Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555044 · ClinicalTrials.gov registry record · Phase 4
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 101
- Enrollment target
NCT04555044 is a Phase 4 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 101 participants.
The verdict
NCT04555044, a Phase 4 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 101 participants
- Enrollment target
Study Summary
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid or Intralipid in a pediatric population.
Interventions
- DRUG Intralipid
- DRUG Clinolipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04555044
The ClinicalTrials.gov registry entry for NCT04555044 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intralipid is the first listed.
NCT04555044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04555044 about?
NCT04555044 is a clinical study titled "Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)". This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safet...
What is the current status of trial NCT04555044?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 101 participants. The study started on 2021-01-22. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT04555044?
The interventions under investigation include: Intralipid (DRUG), Clinolipid (DRUG).
Who is sponsoring clinical trial NCT04555044?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.